Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L. Hudkins, Daniel C. Bensen, Isaac Hoffman et al.|Journal of Medicinal Chemistry|2024Cited by 28